DENTSPLY SIRONA (NASDAQ:XRAY) Posts Quarterly Earnings Results, Beats Estimates By $0.17 EPS

DENTSPLY SIRONA (NASDAQ:XRAY) released its quarterly earnings data on Thursday. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.35 by $0.17, FiscalAI reports. The company had revenue of $898.00 million for the quarter, compared to analyst estimates of $889.93 million. DENTSPLY SIRONA had a positive return on equity of 20.74% and a negative net margin of 14.99%.The firm’s revenue for the quarter was down 4.1% compared to the same quarter last year. During the same period in the previous year, the company posted $0.52 EPS. DENTSPLY SIRONA updated its FY 2026 guidance to 1.400-1.500 EPS.

Here are the key takeaways from DENTSPLY SIRONA’s conference call:

• Q2 revenue declined: Sales fell 4.1% as reported, or 6.3% on a constant-currency basis, with weakness in CAD/CAM, dental consumables, implants and SureSmile. Adjusted EPS was flat at $0.52, while adjusted EBITDA margins were roughly unchanged only after a $44 million tariff refund.
• DENTSPLY SIRONA maintained its 2026 outlook for revenue of $3.5 billion–$3.6 billion and adjusted EPS of $1.40–$1.50, excluding tariff-related effects. Management expects Q3 revenue and earnings to decline sequentially because of seasonality and planned investments.
• The company said the U.S. recovery remains its top priority, but commercial-force training and dealer expansion are expected to have a larger impact in 2027 rather than this year. Management also acknowledged that the U.S. is currently lagging competitors in implants and that SureSmile remains pressured.
• Management reported progress on its 24-month Return-to-Growth plan, including expanded dealer partnerships, clinical education, sales-force certification and increased R&D investment, with improvements expected to become more visible in Q4. DS Core adoption and double-digit APAC milling-system growth were cited as encouraging signs.
• Wellspect remained a bright spot, with revenue up 7.1% on continued new-product sales and geographic expansion. Operating cash flow rose to $99 million from $48 million, and the company repurchased 1.3 million shares while continuing to prioritize debt reduction.

DENTSPLY SIRONA Stock Performance

Shares of XRAY opened at $12.12 on Friday. DENTSPLY SIRONA has a 12-month low of $9.40 and a 12-month high of $14.86. The company has a current ratio of 1.53, a quick ratio of 0.98 and a debt-to-equity ratio of 1.52. The company has a market cap of $2.43 billion, a PE ratio of -4.41, a price-to-earnings-growth ratio of 1.57 and a beta of 0.85. The stock has a 50-day moving average price of $11.77 and a 200-day moving average price of $11.89.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of DENTSPLY SIRONA in a research report on Monday. Citigroup assumed coverage on shares of DENTSPLY SIRONA in a research report on Wednesday, April 15th. They issued a “sell” rating and a $10.00 price objective for the company. Mizuho reduced their price objective on shares of DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. Barclays decreased their target price on shares of DENTSPLY SIRONA from $12.00 to $9.00 and set an “underweight” rating on the stock in a report on Thursday, June 4th. Finally, Piper Sandler raised their price target on shares of DENTSPLY SIRONA from $13.00 to $14.00 and gave the company a “neutral” rating in a report on Wednesday, July 29th. Three investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, DENTSPLY SIRONA presently has an average rating of “Hold” and an average price target of $13.54.

DENTSPLY SIRONA News Roundup

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Adjusted earnings exceeded expectations: Q2 EPS was $0.52, above analyst estimates ranging from $0.35 to $0.36 and matching the year-ago result. Revenue of $898 million also surpassed the roughly $890 million consensus. Dentsply International Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Margins improved: Management highlighted better margins during the quarter, helping offset softer demand and supporting the earnings beat. The Wellspect business was a key sales-growth contributor. XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales
• Neutral Sentiment: Full-year EPS guidance was maintained: DENTSPLY SIRONA reiterated 2026 adjusted EPS guidance of $1.40 to $1.50, which brackets the approximately $1.42 analyst consensus. DENTSPLY SIRONA Second-Quarter 2026 Results
• Negative Sentiment: Sales declined year over year: Q2 revenue fell 4.1%, as weakness in the company’s core dental business outweighed growth at Wellspect. This suggests that broader dental-market demand and utilization remain pressured. XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales
• Negative Sentiment: Revenue guidance was cautious: The company forecast 2026 revenue of $3.5 billion to $3.6 billion, with the midpoint below the $3.6 billion consensus estimate. Investors appear to be prioritizing the weak organic-sales trend and outlook over the quarterly EPS beat.

Insider Buying and Selling

In related news, Director Brian T. Gladden purchased 9,985 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were purchased at an average price of $10.02 per share, with a total value of $100,049.70. Following the acquisition, the director directly owned 61,849 shares of the company’s stock, valued at approximately $619,726.98. This represents a 19.25% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Brian P. Mckeon acquired 10,000 shares of the stock in a transaction dated Friday, June 12th. The shares were bought at an average price of $10.12 per share, for a total transaction of $101,200.00. Following the transaction, the director owned 10,000 shares in the company, valued at approximately $101,200. This represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have purchased 35,160 shares of company stock worth $351,179. Insiders own 0.46% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in DENTSPLY SIRONA during the first quarter worth about $26,000. Caitong International Asset Management Co. Ltd raised its holdings in shares of DENTSPLY SIRONA by 337.9% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier’s stock valued at $35,000 after buying an additional 2,122 shares in the last quarter. Kestra Advisory Services LLC purchased a new position in shares of DENTSPLY SIRONA during the 4th quarter valued at about $56,000. Persistent Asset Partners Ltd bought a new stake in DENTSPLY SIRONA in the 4th quarter worth approximately $98,000. Finally, Compound Planning Inc. bought a new stake in DENTSPLY SIRONA in the 4th quarter worth approximately $117,000. 95.70% of the stock is currently owned by hedge funds and other institutional investors.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.